277 related articles for article (PubMed ID: 35087759)
1. Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.
Piazza F; Di Paolo V; Scapinello G; Manni S; Trentin L; Quintieri L
Front Oncol; 2021; 11():801124. PubMed ID: 35087759
[TBL] [Abstract][Full Text] [Related]
2. Current approach to Waldenström macroglobulinemia.
Kapoor P; Rajkumar SV
Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
Sekiguchi N
Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
[TBL] [Abstract][Full Text] [Related]
4. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
6. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
Wang W; Lin P
Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
[TBL] [Abstract][Full Text] [Related]
7. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
[TBL] [Abstract][Full Text] [Related]
8. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
[TBL] [Abstract][Full Text] [Related]
9. Waldenström macroglobulinemia: biology, genetics, and therapy.
Paludo J; Ansell SM
Blood Lymphat Cancer; 2016; 6():49-58. PubMed ID: 31360080
[TBL] [Abstract][Full Text] [Related]
10. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept.
Lin P; Medeiros LJ
Adv Anat Pathol; 2005 Sep; 12(5):246-55. PubMed ID: 16210920
[TBL] [Abstract][Full Text] [Related]
11. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
Thomas SK
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
[TBL] [Abstract][Full Text] [Related]
12. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with
Zhu J; Zhu X; Xie F; Ding Y; Lu H; Dong Y; Li P; Fu J; Liang A; Zeng Y; Xiu B
Pathol Oncol Res; 2023; 29():1611070. PubMed ID: 37151353
[No Abstract] [Full Text] [Related]
13. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
14. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
15. [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].
Timár B
Magy Onkol; 2017 Mar; 61(1):6-11. PubMed ID: 28273183
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
Brandefors L; Sander B; Lundqvist K; Kimby E
Br J Haematol; 2022 Mar; 196(6):1362-1368. PubMed ID: 34959252
[TBL] [Abstract][Full Text] [Related]
17. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
[TBL] [Abstract][Full Text] [Related]
18. Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression.
Cautha S; Gupta S; Hanif A; Moirangthem V; Jain K
Eur J Case Rep Intern Med; 2022; 9(2):003106. PubMed ID: 35265542
[TBL] [Abstract][Full Text] [Related]
19. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.
Rossi D
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843
[TBL] [Abstract][Full Text] [Related]
20. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
Castillo JJ; Itchaki G; Gustine JN; Meid K; Flynn CA; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
Leuk Lymphoma; 2020 Jun; 61(6):1388-1394. PubMed ID: 31992103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
